
MENLO PARK, Calif., October 23, 2026--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company developing novel small molecule therapeutics derived from i…
ANTX is up 13.86% today. Volume is 387.7K vs a 30-day average of 295.5K (1.31x).
AN2 Therapeutics, Inc. is scheduled to report earnings Thu, Nov 5, 2026. Analysts expect EPS of $-0.20. Stocks often move sharply on earnings day.

MENLO PARK, Calif., October 23, 2026--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company developing novel small molecule therapeutics derived from i…

MENLO PARK, Calif., October 21, 2026--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small mol…

MENLO PARK, Calif., October 20, 2026--AN2 Therapeutics, Inc. (NASDAQ: ANTX), a clinical stage biopharmaceutical company discovering and developing novel small molecule therapeutic…